PLEASANTON, Calif., May 19, 2021 — A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems (NYSE: VEEV) in an industrywide shift to streamline drug development.
More than 650 companies use Veeva Development Cloud applications today, and more than 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams.
Veeva Development Cloud brings together suites of unified applications for clinical, regulatory, quality, and safety on a single cloud platform, eliminating organizational siloes. More than 350 companies are accelerating trial execution with Vault Clinical applications, more than 250 are streamlining regulatory processes with Vault RIM, more than 350 are unifying quality management with Vault Quality, and more than 35 are improving pharmacovigilance with Vault Safety.
Vault Connections in Veeva Development Cloud drive cross-functional business processes across the product lifecycle. For example, Connections enable companies to bring together clinical operations and regulatory for faster submissions; quality and regulatory for simplified change control and variation management; and clinical data and operations for real-time visibility into patient enrollment.
“We’re dedicated to bringing innovations to market that help the industry accelerate drug development,” said Jim Reilly, vice president of Veeva Vault R&D. “Veeva Development Cloud is enabling customers to improve collaboration across teams and speed the delivery of treatments to patients.”
What customers are saying about Veeva Development Cloud:
“Managing drug development across multiple siloed systems is no longer sustainable to move with speed and efficiency,” said Klaas Boone, senior director, business information systems at argenx. “We’re passionate about making what we do better, and using Veeva Development Cloud applications to connect our teams will help drive innovation from clinical trial through regulatory submission and manufacturing.”
“Bringing together clinical operations and regulatory submissions enables real-time availability of protocols, investigational brochures, and other key study documents that help us remain compliant,” said Dee DeOliveira, global director, regulatory operations at Cerevel Therapeutics. “We’re thrilled with how Vault Connections enable collaboration, and we’ve just scratched the surface on the processes that can be enhanced or automated to speed development.”
“We’re unifying clinical and regulatory to facilitate information sharing across teams,” said Jim Clark, IT Veeva center of excellence leader at Spark Therapeutics. “Having Veeva Vault suites in place, all connected, in the cloud, is critically important to ensure continued development success.”
Image Courtesy Veeva
This article was shared with Prittle Prattle News as a Press Release by PRNewswire.
